Wall Street Breakfast Carvana drops despite higher sales
5 snips
Feb 19, 2026 Carvana sees higher sales but shrinking per-vehicle profit, sparking a sharp stock drop. DoorDash posts double-digit order growth and issues upbeat near-term guidance. Moderna gets FDA acceptance to review its seasonal flu mRNA filing with an August action date. Markets update covers big movers, commodities, and tech earnings trends like Figma's strong growth outlook.
AI Snips
Chapters
Transcript
Episode notes
Sales Growth Masked Profitability Weakness
- Carvana sold more cars than expected but profitability weakened, driving the stock down sharply.
- Revenue jumped 58% yet gross profit per vehicle fell and adjusted EPS reflected one-time items.
Prioritize Growth Visibility Over Short-Term Margins
- Focus on demand momentum and guidance even if margins soften, as investors often reward growth visibility.
- DoorDash showed orders and GOV above expectations and gave upbeat Q1 outlook that lifted the stock.
Regulatory Reversal Clears Path For Moderna Shot
- The FDA reversed course and will review Moderna's mRNA flu shot after an amended BLA and regulatory discussions.
- Moderna aims to launch mRNA-1010 for adults 50+ pending a target action date of August 5th.